Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Patients and the Public Recognize and Thank Dedicated Nurses
    Nurse empowerment
    Patients and the Public Recognize and Thank Dedicated Nurses
    May 06, 2022
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    Cancer screening
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    March 18, 2022
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    Oncology nurse pride
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    February 11, 2022
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    Oncology nurse pride
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    January 31, 2022
    The Case of the Post-Transplant Pulmonary Problem
    Clinical practice
    The Case of the Post-Transplant Pulmonary Problem
    January 14, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    BRAF Mutations Guide Treatment in Metastatic Colorectal Cancer
    Clinical practice

    BRAF Mutations Guide Treatment in Metastatic Colorectal Cancer

    Molecular profiling has become essential for the treatment of metastatic colorectal cancer (CRC) when surgery cannot be considered and systemic therapy is recommended. CRC has several potential mutations that are diagnostic, prognostic, and predictive. National Comprehensive Cancer Network (NCCN) guidelines recommend that advanced practice providers conduct RAS, BRAF, HER2, and MSI testing as part of a full molecular panel, review the results, and acted on them prior to starting patients on systemic therapy.

    February 24, 2020
    How DNA Sequencing Technologies Are Used in Cancer Care, Now and in the Future
    Genetics & genomics

    How DNA Sequencing Technologies Are Used in Cancer Care, Now and in the Future

    Genomic testing identifies germline or inherited DNA changes that increase a person’s cancer risk, and it also can identify or profile the somatic or acquired changes in a tumor that guide selection of appropriate targeted therapies. The latter type of genomic testing is an analysis of DNA sequence information.

    February 20, 2020
    The Case of the CDK4/6 Inhibitors Checklist
    Immunotherapy

    The Case of the CDK4/6 Inhibitors Checklist

    Three years ago, Sarah, age 54, completed standard chemotherapy and radiation treatment for stage II, ER- and PR-positive, HER2-negative invasive breast cancer. A recent computed tomography scan, ordered to evaluate persistent hip pain, revealed bone lesions, and a biopsy and positron-emission tomography scan confirmed bone-only metastatic breast cancer. A CDK4/6 inhibitor, ribociclib, was added to the letrozole she was already taking.

    February 18, 2020
    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer
    Clinical practice

    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer

    Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).

    February 11, 2020
    Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations
    Ovarian cancer

    Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations

    Even though its incidence is less common, ovarian cancer is the fifth leading cause of death from cancer in women, according to the American Cancer Society. It also estimated more than 22,000 new cases of ovarian cancer in 2019, with a five-year survival of 47% for all stages.

    February 06, 2020
    Updated NCCN Cancer Screening Guidelines Inform Practice and Prevention
    Clinical practice guidelines

    Updated NCCN Cancer Screening Guidelines Inform Practice and Prevention

    As an industry standard, the National Comprehensive Cancer Network (NCCN) screening guidelines have served a huge role in cancer prevention and early detection efforts, helping providers identify diagnoses early and give patients their best possible chance at survival. Ensuring screening guidelines are up to date and using the best available evidence is an ongoing process that requires an interprofessional approach.

    February 04, 2020
    The Value of Vigilance: New Screening Recommendations Are Vital for Cancer Prevention
    Cancer screening

    The Value of Vigilance

    Although society still hopes for that one big discovery to cure cancer, clinicians know that there’s already a tried and true method to give patients their best shot at survival: catching a diagnosis early or preventing one altogether.

    February 04, 2020
    Nurses Can Protect Patients From Neurotoxicity During Lumbar Puncture Procedures
    Clinical practice

    Nurses Can Protect Patients From Neurotoxicity During Lumbar Puncture Procedures

    When cleaning patients’ skin in preparation for lumbar puncture procedures, oncology nurses must consider side effects from use of various germicide solutions. Chlorhexidine gluconate (CHG) solution has been considered the broad-spectrum germicide effective against most nosocomial yeasts and gram-positive and -negative bacteria. It’s available as 2% or 5% CHG in 70% isopropyl alcohol and is used as an antiseptic for skin preparation and central venous catheter dressings.

    January 28, 2020
    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up
    Treatments

    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up

    January 22, 2020
    Oncology Drug Reference Sheet: Entrectinib
    Treatments

    Oncology Drug Reference Sheet: Entrectinib

    Entrectinib was approved by the U.S. Food and Drug Administration in August 2019 as the third tumor-agnostic cancer drug, meaning it targets a specific mutation of the cancer, not the organ of origin. The other two currently approved tumor-agnostic drugs are larotrectinib and pembrolizumab.

    January 21, 2020
    Prioritize Your Time Amid Today’s Attention Seekers
    Nurse well-being

    Prioritize Your Time Amid Today’s Attention Seekers

    In a world where we are bombarded with too many attention seekers (e.g., activities, people, internet), we need to prioritize which stimuli are worth our immediate attention. Nurses are inundated with busy, fast-paced, and evolving roles, and 90% report that they do not have enough time to properly care for patients. The pressure to do so much in a limited amount of time increases stress levels and burnout and decreases our capacity for self-care. Prioritizing and devoting allotted time to our attention seekers may improve stress management, work-life balance, and overall self-care.

    January 16, 2020
    Breast Cancer Is More Fatal in Men Than Women
    Breast cancer

    Breast Cancer Is More Fatal in Men Than Women

    Men have higher death rates than women across all stages of breast cancer, study findings reported in JAMA Oncology show. In the study, five-year overall survival after a breast cancer diagnosis was 77.6% for men and 86.4% for women.

    January 15, 2020
    Germline and Somatic Variants: What Is the Difference?
    Genetics & genomics

    Germline and Somatic Variants: What Is the Difference?

    Cancer occurs from pathogenic genetic variants (formerly referred to as mutations) that involve changes in the order of the base pairs, including substitutions, deletions, additions, or shifts. Pathogenic variants can be divided into two broad categories based on the tissue from which they originate.

    January 14, 2020
    What the Research Cautions About Kratom’s Opioid-Like Abuse Potential
    Complementary therapy

    What the Research Cautions About Kratom’s Opioid-Like Abuse Potential

    Kratom is a Southeast Asian tropical tree, the leaves of which have been chewed, smoked, or made as tea for their stimulant and euphoric effects. They have also been employed in traditional medicine to reduce pain and fever, to relieve diarrhea, for wound healing, and as a substitute for opium. Recently, kratom supplements have become popular in the United States for alleviating pain, improving mood, lowering anxiety, and alternative opioid withdrawal treatment.

    January 13, 2020
    FDA Approves Avapritinib for Gastrointestinal Stromal Tumor With a Rare Mutation
    U.S. Food and Drug Administration (FDA)

    FDA Approves Avapritinib for Gastrointestinal Stromal Tumors With a Rare Mutation

    On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved avapritinib (AyvakitTM) for adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation, including D842V mutations.

    January 10, 2020
    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

    On January 8, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.  

    January 08, 2020
    Does Cryotherapy Prevent Extremity Toxicities From Taxane Chemotherapy?
    Treatment side effects

    Does Cryotherapy Prevent Extremity Toxicities From Taxane Chemotherapy?

    As many as 50% of patients receiving taxane chemotherapy have reported experiencing peripheral neuropathy (PN) or nail changes during treatment. Both are potentially dose-limiting adverse events: nail changes can lead to infections; PN affects patients’ ability to perform activities of daily living and results in sensory impairments such as loss of balance, muscle weakness, and numbness that can increase patients’ risk for falls.

    January 07, 2020
    CAR T-Cell Therapy Offers Rapid QOL Improvements in Younger Patients
    Patient quality of life

    CAR T-Cell Therapy Offers Rapid QOL Improvements in Younger Patients

    Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia reported rapid improvements in quality of life (QOL) after treatment with tisagenlecleucel, a CAR T-cell therapy, according to the results of a study published in Lancet Oncology.

    January 01, 2020
    New Patient Education Formats Help Nurses Connect Patients to Individualized Resources
    Patient Education

    New Patient Education Formats Help Nurses Connect Patients to Individualized Resources

    “An investment in knowledge pays the best interest,” Benjamin Franklin wrote. for oncology nurses and their patients, this couldn’t be more apt. Patient education is critical throughout the cancer journey, and nurses are essential to individualizing that education.

    January 01, 2020
    Commission on Cancer Revises Its Standards. Here Are the Takeaways for Oncology Nurses.
    Standards

    Commission on Cancer Revises Its Standards. Here Are the Takeaways for Oncology Nurses.

    Oncology nurses are critical to meeting three components of the newly revised Commission on Cancer (CoC) standards released in fall 2019: certification, survivorship, and barriers to care.

    December 30, 2019
    Oncology Drug Reference Sheet: Radium 223 Dichloride
    Treatments

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

    On December 20, 2019, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

    December 20, 2019
    Multigene Testing Is Cost Effective for All Women With Breast Cancer
    Genetics & genomics

    Multigene Testing Is Cost Effective for All Women With Breast Cancer

    According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

    December 20, 2019
    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer

    On December 18, 2019, the U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (PadcevTM) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

    December 19, 2019
    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells
    Research

    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells

    Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.

    December 18, 2019
    Newer Therapies at Last Offer Systemic Options for Metastatic HCC
    Advanced practice nursing (APN)

    Newer Therapies at Last Offer Systemic Options for Metastatic HCC

    Already the third leading cause of cancer deaths worldwide, hepatocellular carcinoma (HCC) is a continually growing burden as the incidence of obesity, type II diabetes, and hypertension also increase, which may lead to cirrhosis and nonalcoholic fatty liver disease. Its incidence is highest in Asia and Africa, where the prevalence of hepatitis B and hepatitis C may result in chronic liver disease and subsequently HCC. 

    December 12, 2019
    Evidence-Based Program Reduced C. Difficile Incidence in Patients With Cancer
    Clinical practice

    Evidence-Based Program Reduced C. Difficile Incidence in Patients With Cancer

    Clostridium difficile infection is a dangerous and sometimes deadly adverse event in immunocompromised patients with cancer. Although transmission risk is high in the hospital setting, even with isolation precautions, oncology providers can use a variety of prevention techniques to reduce the chance for infection in their patients.

    December 10, 2019
    B. Braun Recalls Certain Lots of Blood Administration Sets
    Safety

    B. Braun Recalls Certain Lots of Blood Administration Sets

    Because of the potential for leakage at the joint between the blood filters and tubing, B. Braun issued a voluntary recall of 22 lots of its y-type blood administration sets in November 2019. The recalled sets are used to deliver blood from a container to a patient's vascular system through an IV catheter inserted into a vein or central venous catheter.

    December 03, 2019
    Evidence Drives the Development of Guidelines for Practice
    Clinical practice guidelines

    Evidence Drives the Development of Guidelines for Practice

    Evidence-based practice is central to successful patient care—not only in oncology but throughout the entire healthcare community. Currently, the way health care is delivered varies throughout the United States. Not all hospitals or clinics are the same, nor do all institutions operate the same. Many treatments are given to patients without clear evidence of the benefit, and unity and standardization are lacking, which could lead to wide variances in the efficacy and safety of care provided to patients.

    December 03, 2019
    Draft ONS Guideline Open for Public Comment
    Clinical practice guidelines

    Draft ONS Guideline Open for Public Comment

    As part of the rigorous process of transitioning ONS Putting Evidence Into Practice recommendations into formal, actionable clinical practice guidelines, the draft guidelines must undergo a public comment period. The first five guidelines to reach that step will be open for public comment in December 2019 and early 2020.

    December 02, 2019
    From Evidence to Standard: The Role of Clinical Guidelines in Oncology Care
    Clinical practice guidelines

    From Evidence to Standard: The Role of Clinical Guidelines in Oncology Care

    Leading organizations like ONS develop nationally recommended, evidence-based cancer care guidelines to inform practice, unify and standardize the way patient care is delivered, and ensure successful outcomes. By clarifying gray areas and codifying practice, guidelines enable providers to deliver efficacious, safe oncology care for patients and all care providers.

    December 02, 2019
    Oncology Drug Reference Sheet: Blinatumomab (Blincyto®)
    Treatments

    Oncology Drug Reference Sheet: Blinatumomab

    Blinatumomab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of B-cell precursor acute lymphoblastic leukemia. The drug’s unique administration procedures have prompted nurses to evaluate their practice for safety.

    November 27, 2019
    Cope With Moral Distress by Focusing on the Possibilities
    Nurse well-being

    Cope With Moral Distress by Focusing on the Possibilities

    Ethical dilemmas arise more often than we realize: consider the patient you have been taking care of for three days telling you he wants no further treatment, but later goes along with family members when they push for more treatment. Moral distress occurs when nurses believe they know the correct action to take but are prevented from doing so. It may lead to a decrease in the quality of patient care and can be a causative factor when nurses leave their current job and sometimes even the profession.

    November 26, 2019
    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?
    Research

    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?

    Receiving antibiotics in the 30 days prior to starting immune checkpoint inhibitor treatment was associated with significantly reduced median overall survival, according to findings from a study published in JAMA Oncology. However, antibiotic use during treatment had no effect on survival.

    November 20, 2019
    The Case of the Efficacy Explanation
    Treatments

    The Case of the Efficacy Explanation

    Jenni is an oncology nurse practitioner in an outpatient medical oncology clinic. She is meeting with 70-year-old Don after his first cycle of cabozantinib for treatment of metastatic medullary thyroid carcinoma when he asks why the oncologist put him on a pill instead of using IV chemotherapy. “Is it because I don’t have long to live?” Don wonders.

    November 19, 2019
    The Vital Role of Oncology Nursing in Ambulatory Care
    Oncology nursing roles

    The Vital Role of Oncology Nursing in Ambulatory Care

    Thanks to significant scientific and technologic advancements in the past 15 years, the majority of cancer care—an estimated 80% or higher—is being delivered in the outpatient setting.For patients, ambulatory oncology care offers comfort, flexibility, and a sense of normalcy during their difficult cancer journey while maintaining the highest-level treatment and care for optimal outcomes. Oncology nurses are key to successful outpatient care, serving as caregivers, educators, advocates, and patient champions from diagnosis through treatment and into survivorship.

    November 05, 2019
    Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents
    Advanced practice nursing (APN)

    Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents

    As a side effect of cancer or its treatment, anemia is associated with reduced quality of life, thanks to symptoms such as palpitations, fatigue, dyspnea, and dizziness. Etiology is often multifactorial with contributing factors such as suppression of hematopoiesis from malignancy or cancer treatments, bleeding, nutritional deficiencies, renal insufficiency, or hemolysis.

    October 31, 2019
    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer
    Research

    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer

    A test that looks at circulating DNA rather than specific mutations is accurate in detecting 72% of early cancer cases and correctly identifying the tissue of origin in 75% of cases, researchers reported in study findings published in Nature.

    October 30, 2019
    Harness Stress for Focus and Productivity
    Nurse well-being

    Harness Stress for Focus and Productivity

    Stress is generally associated with negative mental and physical consequences. But can it actually be a healthy, even sought-after phenomenon at times?

    October 29, 2019
    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages
    U.S. Food and Drug Administration (FDA)

    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages

    A manufacturing delay leading to a shipping delay caused the October 2019 vincristine shortage, according to a letter Pfizer sent to its customers on October 18; the U.S. Food and Drug Administration first reported the shortage on October 16. It affects both the 1 mg/ml and 2 mg/2 ml single-dose ONCO-TAIN™ glass fliptop vials.

    October 22, 2019
    Oncology Drug Reference Sheet: Darolutamide (Nubeqa®)
    Treatments

    Oncology Drug Reference Sheet: Darolutamide

    Based on the results of the phase III ARAMIS trial that demonstrated significant improvement in metastasis-free survival, the U.S. Food and Drug Administration approved darolutamide under priority review on July 30, 2019. Darolutamide is approved for nonmetastatic, castration-resistant prostate cancer in men receiving concurrent gonadotropin-releasing hormone therapy or who have had bilateral orchiectomy.

    October 22, 2019
    Should You Wear a Gown to Disconnect Chemo?
    Safety

    Should You Wear a Gown to Disconnect Chemo?

    The short answer is yes—guidelines from ONS, National Institute of Occupational Safety and Health, Occupational Safety and Health Administration, and U.S. Pharmacopia all call for nurses to always wear appropriate personal protective equipment (PPE) when at risk for exposure, including disconnecting a patient’s chemotherapy. Wearing a gown and other PPE isn’t just good practice—it protects nurses at one of many touchpoints during chemotherapy administration and patient care where healthcare providers are at risk for exposure to hazardous drugs.

    October 21, 2019
    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50
    Clinical practice

    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50

    Healthcare providers are seeing increasing numbers of younger patients with colorectal cancer, and they’re being diagnosed with more advanced stages of the disease, researchers reported in study findings published in the journal Cancer.

    October 16, 2019
    The Case of the Nicotine Nightmare
    Cancer risk factors

    The Case of the Nicotine Nightmare

    Jill works as an oncology nurse in a large community hospital. While attending a family gathering, her uncle proudly tells her that he and his 17-year-old son are using e-cigarettes to help them stop smoking traditional cigarettes. He comments that his wife now allows them to “smoke” in the house and car because the vapor is relatively odor free.

    October 15, 2019
    Cancer Rehabilitation Serves a Critical Role in Patient Care
    Prehabilitation

    Cancer Rehabilitation Serves a Critical Role in Patient Care

    More and more providers are recognizing that prehabilitation and rehabilitation are key components of successful patient-centered cancer care. Oncology nurses serve as a critical access point to those services and must understand rehabilitation and its indications. To better highlight cancer rehabilitation’s benefits and importance in clinical practice, ONS members Grace Campbell, PhD, MSW, RN, CNL, CRRN, and Beverly Reigle, PhD, RN, shared a conversation about the finer points of cancer rehabilitation specialty practice.

    October 11, 2019
    irAEs Linked to Improved Benefit From Pembrolizumab
    Immunotherapy

    irAEs Linked to Improved Benefit From Pembrolizumab

    Patients with advanced melanoma who received adjuvant therapy with pembrolizumab and subsequently developed immune-related adverse events (irAEs) saw a 63% reduced risk of recurrence, compared to 44% for those who did not develop irAEs. The study findings were presented at the 2019 American Society of Clinical Oncology annual meeting.

    October 09, 2019
    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors
    Immunotherapy

    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors

    By rebalancing the immune system and re-engaging mechanisms that tumor cells have shut off, immunotherapies such as immune checkpoint inhibitors enable patients’ own bodies to fight their cancers for them. But those same mechanisms can also result in immune-related adverse events (irAEs).

    October 08, 2019
    Complexity Is the Cornerstone of BMT Nursing
    Oncology nursing roles

    Complexity Is the Cornerstone of BMT Nursing

    You’re juggling three patients: one is nauseated and requesting lorazepam now, another’s blood transfusion is finished and the pump’s alarm is loudly chirping down the hall, the third has an order list coming in like rapid fire—and it’s only 8 am. In a blood and marrow transplant (BMT) unit, this sounds like a relatively calm morning.

    October 07, 2019
    What the Research Says About Drug Interactions and Medical Cannabis
    Oncology drug research

    What the Research Says About Drug Interactions and Medical Cannabis

    Despite medical cannabis’s legalization for medical use throughout 31 different jurisdictions in the United States, practicing providers have little research and few guidelines for patient care. To address the gap, in 2018 the National Council of State Boards of Nursing published Nursing Guidelines for Medical Marijuana, which provides general nursing education and guidance—yet doesn’t discuss drug interactions, specifically. To understand how medical cannabis affects concomitant pharmaceuticals, nurses must have a basic knowledge of the endocannabinoid system (ECS).  

    October 04, 2019
    Patient-Centered Care Through the Oncology Care Model
    Quality of care

    Patient-Centered Care Through the Oncology Care Model

    Better care. Smarter spending. Healthier people. Those are the three hallmark goals of the Oncology Care Model, a value-based payment system developed by the Centers for Medicare and Medicaid Service’s Center for Innovation.

    October 01, 2019
    • First page « First
    • Previous page
    • …
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Current page 8
    • Page 9
    • Page 10
    • Page 11
    • Page 12
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲